Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.
George L Bakris, Mitra K Nadim, Hermann Haller...
https://pubmed.ncbi.nlm.nih.gov/22341199/Actively Recruiting
Led by CVRx, Inc. · Updated on 2026-09-11
500
Participants Needed
26
Research Sites
N/A
Total Duration
This research aims to evaluate the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people recently implanted with this device for resistant hypertension. The study observes patients implanted under the CE-Marked indication to assess how the therapy works in a commercial setting. The registry includes participants implanted within the past 30 days who meet specific blood pressure and medication resistance criteria. Participants in this registry have the BAROSTIM NEO System implanted and are followed over time without additional treatment interventions, as this is an observational study. Data are collected from standard medical care measurements taken before implantation, at enrollment, and at 3, 6, and 12 months after implantation. After the first year, data collection continues every six months for up to three years, providing long-term observation of therapy impact. During the study, participants undergo regular assessments of blood pressure, changes in cardiovascular medications, and health care use from before implant through three years post-implant. Researchers collect this information during routine care visits, and participants remain under usual medical supervision. The total participation duration can be up to three years from implantation, with data collected at scheduled intervals to monitor the therapys ongoing effects.
CONDITIONS
BAROSTIM THERAPY™ In Resistant Hypertension
N
Nicole Baumann
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
CVRx, Inc.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 3 years
Participants are observed after implantation with the BAROSTIM NEO System, with data collected from standard medical care visits including blood pressure, medication changes, and health care use.
Data collected at enrollment, 3, 6, 12 months, then every 6 months up to 3 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
George L Bakris, Mitra K Nadim, Hermann Haller...
https://pubmed.ncbi.nlm.nih.gov/22341199/John D Bisognano, George Bakris, Mitra K Nadim...
https://pubmed.ncbi.nlm.nih.gov/21816315/Uta C Hoppe, Mathias-Christoph Brandt, Rolf Wachter...
https://pubmed.ncbi.nlm.nih.gov/22694986/Ingrid J M Scheffers, Abraham A Kroon, Jürg Schmidli...
https://pubmed.ncbi.nlm.nih.gov/20883933/CVRx, Inc.
Lead Sponsor